Establishment of a WHO Reference Reagent for anti-Mullerian hormone

Table 4 Assessment of the commutability of 16/190 with representative patient samples

Laboratory	Mean Patient Sample Bias	Lower Limit	Upper Limit	Mean 16/190 bias	16/190 Slope	Patient Samples Slope
1	−0.029	− 0.078	0.021	− 0.149	1.02	1.04
2	0.137	0.088	0.187	0.143	0.98	1.08
3	0.045	−0.005	0.094	0.348	1.02	0.98
4	−0.014	−0.063	0.036	0.033	1.01	1.04
5	−0.044	−0.094	0.005	0.033	1.00	1.06
6	0.109	0.060	0.159	0.386	1.08	1.07
7	−0.025	− 0.074	0.025	− 0.029	0.97	0.98
9	0.121	0.072	0.171	0.065	0.96	0.95
12	−0.064	− 0.114	− 0.015	0.008	0.99	0.97
13	−0.041	−0.090	0.009	−0.223	1.06	1.06
14	−0.009	− 0.059	0.040	−0.025	1.00	0.97
15	0.023	−0.027	0.072	−0.015	1.02	1.04
16	0.007	−0.042	0.057	−0.002	1.00	0.93
19	−0.078	−0.127	− 0.028	−0.111	1.00	1.03
20	0.042	−0.008	0.091	−0.008	1.00	0.93
21	−0.017	−0.066	0.033	−0.063	1.06	0.97

This shows the mean patient bias for each valid laboratory method, the upper and lower limits of acceptable commutability (±2s_P) for each method and the mean bias values for 16/190 obtained by that method. Values underlined indicate where the mean bias is outside the limits of acceptable bias for that method. As this assessment requires the bias to be constant across the range of AMH concentrations measured, the slope of the bias for 16/190 and the patient samples is also shown

ISSN: 1477-7827